Measles Vaccine Developer Samuel Katz Dies at 95

He also worked on immunizations against polio, rubella, influenza, and more.

| 3 min read
Sam Katz looks at camera

Duke University

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Measles was once a common childhood ailment, claiming millions of lives globally each year. Samuel Katz, one of the primary developers of the attenuated measles vaccine that helped to slash that death toll, died at his home in Chapel Hill, North Carolina, on October 31 at age 95.

Katz was born in New Hampshire on May 29, 1927. According to an obituary from Duke University, he completed a year at Dartmouth College before enlisting in the United States Navy in 1945. Since World War II was nearing its end, he was sent to work in a San Diego hospital. His interest in medicine was piqued, and when he returned to Dartmouth, he completed his undergraduate degree and then a two-year preclinical program in 1950. He attended medical school at Harvard University, graduating in 1952. Katz then stayed in Boston, doing training and fellowships at hospitals around the city.

According to a 2009 alumni profile from Dartmouth, Katz was in the third year of his residency in 1955 when a scourge of polio hit the Boston area. A vaccine against the disease had recently been approved by the US Food and Drug Administration (FDA) but hadn’t yet been widely distributed. Katz and other doctors worked around the clock to see the line of sick children and worried parents outside, using flashlights after the sun went down. This experience prompted him to pursue a career in pediatric infectious diseases.

See “Jean Macnamara’s Multiple Causes, 1931

The previous year, Boston-based virologist John Enders received the Nobel Prize in Physiology or Medicine for isolating the polio virus. The Washington Post reports that Katz contacted him as the polio outbreak abated about joining Enders’s lab at Boston Children's Hospital to work on developing a measles vaccine.

Katz and others infected a series of chicks with the measles virus to successfully attenuate it. Because the virus doesn’t replicate well in chickens, it became weaker each time it infected a new host until the virus induced an immune response without symptoms or active viral infection. By the late 1950s, human trials began, and the vaccine successfully elicited antibodies in the blood of patients without signs of infection by the virus itself. In 1960, Enders, Katz, and their colleagues published their results, which were met with tremendous interest.

See “Bile and Potatoes, 1921

That same year, Katz began work trialing the new vaccine in Nigeria, where the mortality rate for measles was much higher than in the US. The vaccine was given to hundreds of children, and the success of the trial helped get the vaccine licensed. According to the World Health Organization, the vaccine was described as 100 percent effective, and the FDA approved the vaccine in 1963. In 1968, the vaccine Katz worked on was replaced by an even weaker form of the virus that had milder side effects.

The same year, he became the head of pediatrics at the Duke University School of Medicine, a position he held for 22 years. There, Katz worked toward developing immunizations for polio, rubella, influenza, and many other viral diseases. In 1990, he stepped down from this administrative role to focus on pediatric AIDS alongside his second wife, immunologist Catherine Wilfert.

In addition to his official duties at Duke, Katz spent much of his time advocating for pediatric immunizations both globally and in the US. According to a newsletter from the Pediatric Infectious Diseases Society, Katz joined the organization soon after it was founded in 1977. The following year, at the inaugural meeting, he co-led a program promoting the measles vaccine. He was an advisor to the Centers for Disease Control and Prevention on immunizations from 1982 to 1993.

According to the Post, Katz testified before Congress in 1999 on behalf of the American Academy of Pediatrics and the Infectious Disease Society of America, reminding lawmakers what the world was like before childhood vaccinations were commonplace as the Committee on Government Reform debated regulations around mandatory vaccinations versus personal choice.

“Most young parents cannot appreciate, fortunately, as I do, the horror of polio with iron lungs and crutches; measles with encephalitis; meningitis due to haemophilus influenza B . . . the deafness, blindness and brain injury . . . caused by congenital rubella; tetanus of newborn infants with overwhelming mortality; and a number of the other infectious diseases that we fortunately do not see,” he said.

Katz was preceded in death by a son, Samuel, in 1980 and his wife, Catherine Wilfert, in 2020. He is survived by six children, two stepchildren, and 17 grandchildren.

Clarification (November 28): While at Duke University, Samuel Katz worked toward developing vaccines against various viral diseases, but only the measles vaccine he worked on at Boston Children’s Hospital was approved by the Food and Drug Administration and became widely used. The text of the article has been changed to reflect this.

Keywords

Meet the Author

  • Lisa Winter

    Lisa Winter became social media editor for The Scientist in 2017. In addition to her duties on social media platforms, she also pens obituaries for the website. She graduated from Arizona State University, where she studied genetics, cell, and developmental biology.
Share
You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo